PEPFAR’s Short-Term Reauthorization Sets an Uncertain Course for Its Long-Term Future
KFF | Healthcare Policy Issues
by
21h ago
With the new omnibus bill, PEPFAR has been reauthorized until March 25, 2025, without the inclusion of any controversial provisions or changes related to abortion, sought by some. Still, while this latest step provides the program with some short-term certainty, including signaling bipartisan support (albeit limited), it marks a significant departure from PEPFAR’s past ..read more
Visit website
Is Medicaid Too Big to… Block Grant?
KFF | Healthcare Policy Issues
by
2d ago
In his latest column, KFF President and CEO Drew Altman examines how the politics around the Medicaid program have changed as it has grown much larger and more popular, making it even tougher to block grant the program to cut federal Medicaid spending and hand it off to the states ..read more
Visit website
April 3 Virtual Event – Primary Care Check Up: Why It Can Be Hard to Get an Appointment and How to Fix It
KFF | Healthcare Policy Issues
by
3d ago
Primary care has historically served as the backbone of our nation’s health care system, with patients often maintaining a relationship with a primary-care provider to guide their care over a period of years. Yet, the U.S. emphasizes primary care less than other high-income countries. And a shortage of primary-care providers and changes in the marketplace…More ..read more
Visit website
Gross Medicare Spending on Ozempic and Other GLP-1s Is Already Skyrocketing – Even Though Medicare Cannot Cover The Drugs for Weight Loss
KFF | Healthcare Policy Issues
by
5d ago
A KFF analysis shows that gross total Medicare spending on Ozempic and other similar drugs has increased dramatically in recent years – even though Medicare is explicitly prohibited by law from covering the drugs for obesity. That’s because Medicare now covers the drugs, known as GLP-1s, for other medically accepted indications, including to treat diabetes.…More ..read more
Visit website
Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing
KFF | Healthcare Policy Issues
by
6d ago
This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years. Medicare is prohibited from covering drugs used for weight loss, but Medicare Part D plans can cover GLP-1s for their other medically-accepted indications, including to treat diabetes ..read more
Visit website
KFF Dashboard: Progress Toward Global Tuberculosis Targets in USAID TB Priority Countries
KFF | Healthcare Policy Issues
by
6d ago
This dashboard monitors the status of USAID tuberculosis (TB) priority countries’ progress toward global TB targets. It includes data for more than 20 countries in which USAID’s bilateral TB program currently carries out its efforts ..read more
Visit website
Gaps in Data About Hospital and Health System Finances Limit Transparency for Policymakers and Patients
KFF | Healthcare Policy Issues
by
6d ago
This brief describes gaps in data about hospital and health system finances and business practices that limit transparency for policymakers, researchers, and consumers. It examines data issues involving finances, debt collection practices, charity care, prices, ownership, and the 340B Drug Pricing Program ..read more
Visit website
The Supreme Court, Medication Abortion, and the FDA: What’s at Stake?
KFF | Healthcare Policy Issues
by
6d ago
In advance of oral arguments about access to medication abortion before the Supreme Court on March 26, KFF examines how a Court ruling for the plaintiffs would limit access to mifepristone blocking its use in telehealth and distribution through pharmacies, including in states where abortion is legal and protected. In addition, it could potentially weaken…More ..read more
Visit website
What’s at Stake for Access to Medication Abortion and the FDA in the Supreme Court Case FDA v. the Alliance for Hippocratic Medicine?
KFF | Healthcare Policy Issues
by
1w ago
The Supreme Court will be hearing oral arguments for the case FDA v. Alliance for Hippocratic Medicine. This brief explains the issues at stake before the court and their implications for the drug regulatory process and medication abortion access throughout the country ..read more
Visit website
The Impact of the Pandemic on Well-Child Visits for Children Enrolled in Medicaid and CHIP
KFF | Healthcare Policy Issues
by
1w ago
This issue brief examines well-child visit rates overall and for selected characteristics before and after the pandemic began and discusses recent state and federal policy changes that could impact children’s preventive care. More than half of children under age 21 enrolled in Medicaid or CHIP received a well-child visit in 2019, but the share fell to 48% in 2020, the start of the COVID-19 pandemic ..read more
Visit website

Follow KFF | Healthcare Policy Issues on FeedSpot

Continue with Google
Continue with Apple
OR